AP-4-Associated Hereditary Spastic Paraplegia

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 19 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

AP-4-associated hereditary spastic paraplegia (AP-4-HSP) is a group of slowly-progressing neurodegenerative disorders that generally present with global developmental delay, moderate to severe intellectual disability, impaired/absent speech, small head size (microcephaly), seizures, and progressive motor symptoms. Low muscle tone (hypotonia) in infancy develops into high muscle...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

AP-4-associated hereditary spastic paraplegia (AP-4-HSP) is a group of slowly-progressing neurodegenerative disorders that generally present with global developmental delay, moderate to severe intellectual disability, impaired/absent speech, small head size (microcephaly), seizures, and progressive motor symptoms. Low muscle tone (hypotonia) in infancy develops into high muscle tone (hypertonia), resulting in spasticity of the legs that leads to the inability to walk (non-ambulation) and wheelchair reliance. Spasticity...

Key Takeaways

  • This article explains Causes in simple medical language.
  • This article explains Symptoms in simple medical language.
  • This article explains Diagnosis in simple medical language.
  • This article explains Treatment in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

AP-4-associated hereditary spastic paraplegia (AP-4-HSP) is a group of slowly-progressing neurodegenerative disorders that generally present with global developmental delay, moderate to severe intellectual disability, impaired/absent speech, small head size (microcephaly), seizures, and progressive motor symptoms. Low muscle tone (hypotonia) in infancy develops into high muscle tone (hypertonia), resulting in spasticity of the legs that leads to the inability to walk (non-ambulation) and wheelchair reliance. Spasticity may progress to the upper extremities, leading to the partial or total loss of use of all four limbs and torso (tetraplegia).

Causes

AP-4-associated HSP is inherited in an autosomal recessive manner. The four genes that encode subunits of the AP-4 complex are AP4B1, AP4E1, AP4M1, and AP4S1. Parents each carrying a mutated gene have a 25% chance of having an affected child, a 50% chance of having an unaffected carrier child, and a 25% chance of having a child who is unaffected and does not carry a mutated gene.

Diagnosis

The diagnosis of AP-4-associated HSP is based on clinical characteristics and testing that may include a brain MRI showing characteristic features such as a thin corpus callosum, wide lateral ventricles, and changes in the white matter. A definitive diagnosis is reached by genetic testing.

Spastic paraplegia 4 (SPG4; also known as SPAST-HSP) should be suspected in individuals with the following:

  • Characteristic clinical symptoms of insidiously progressive bilateral leg stiffness affecting gait with or without spasticity at rest and mild proximal weakness, often accompanied by urinary urgency
  • Neurologic examination demonstrated corticospinal tract deficits affecting both legs (spastic weakness, hyperreflexia, and extensor plantar responses). Mildly impaired vibration sensation in the ankles is present in the majority of individuals.
  • Family history consistent with autosomal dominant inheritance, or exclusion of other causes of spastic paraplegia in simplex cases (i.e., a single occurrence in a family)

Note: The presence of other signs/symptoms suggestive of complicated hereditary spastic paraplegia does not exclude SPAST-HSP, although it reduces its probability.

Brain and spinal cord MRI

  • Often normal in individuals with SPAST-HSP
  • Spinal cord atrophy can occur in SPAST-HSP, but is less pronounced than in other genetic causes of HSP.
  • Mild vermis atrophy, a thin corpus callosum, subtle white matter changes, and/or cerebellar atrophy have been reported [, ].
  • Electromyography (EMG) with nerve conduction velocities (NCV) is used to exclude peripheral nervous system involvement, which could raise the possibility of an alternative diagnosis as severe polyneuropathy is not a frequent symptom of SPAST-HSP. Karle et al performed neurophysiologic examinations of 128 individuals with HSP, including 35 individuals with SPAST-HSP, and showed that massively elongated central motor conduction time argued against SPAST-HSP; however, reduced amplitudes and prolonged latencies were reported, in particular in individuals with a SPAST pathogenic  variant [].
  • Single- testing. Sequence analysis of SPAST detects , , and  variants, as well as small intragenic deletions/insertions. The combination of in silico predictive algorithms and information retrieved from population databases is essential to establish the pathogenic role of variants of  []. If no  is found on sequence analysis, perform gene-targeted  to detect intragenic deletions or duplications.
  • A  that includes SPAST and other genes of interest is most likely to identify the genetic cause of the condition while limiting the identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each  vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests. For this disorder, a multigene panel that also includes deletion/duplication analysis is recommended

Treatment

No specific treatment is known that would prevent, slow, or reverse HSP. Available therapies mainly consist of symptomatic medical management and promoting physical and emotional well-being. Therapeutics offered to HSP patients include:

  • Baclofen – a voluntary muscle relaxant to relax muscles and reduce tone. This can be administered orally or intrathecally.
  • Tizanidine – to treat nocturnal or intermittent spasms (studies available )
  • Diazepam and clonazepam – to decrease the intensity of spasms
  • Oxybutynin chloride – an involuntary muscle relaxant and spasmolytic agent, used to reduce spasticity of the bladder in patients with bladder control problems
  • Tolterodine tartrate – an involuntary muscle relaxant and spasmolytic agent, used to reduce spasticity of the bladder in patients with bladder control problems
  • Cro System – to reduce muscle overactivity (existing studies for spasticity
  • Botulinum toxin – to reduce muscle overactivity (existing studies for HSP patients
  • Antidepressants – (such as selective serotonin reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors) – for patients experiencing clinical depression
  • Physical therapy – to restore and maintain the ability to move; to reduce muscle tone; to maintain or improve range of motion and mobility; to increase strength and coordination; to prevent complications, such as frozen joints, contractures, or bedsores

Management of symptoms

  • Ages 0-3 years. Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy as well as mental health services, special educators, and sensory-impairment specialists.
  • Ages 3-5 years. In the United States, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed for those who qualify based on the established motor, language, social, and/or cognitive delay. The early intervention program typically assists with this transition.
  • Ages 5-21 years. In the United States, an IEP based on the individual’s level of function should be developed by the local public school district and will dictate specially designed instruction/related services. Discussion about transition plans including financial and medical arrangements should begin at the age of 12 years. Developmental pediatricians can assist with the transition to adulthood.

Motor Dysfunction

  • Gross motor dysfunction – Physical therapy is recommended to maximize mobility.Consider the use of durable medical equipment and positioning devices as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, and adaptive strollers).
  • Fine motor dysfunction – Occupational therapy is recommended for difficulty with fine motor skills that affect adaptive functions such as feeding, grooming, dressing, and writing.
  • Oral-motor dysfunction – Oral-motor dysfunction should be reassessed at regular intervals and clinical feeding evaluations and/or radiographic swallowing studies should be obtained for choking/gagging during feeds, poor weight gain, frequent respiratory illnesses, or feeding refusal that is not otherwise explained.
  • Communication issues – Speech therapy is recommended. Consider evaluation for alternative means of communication for individuals who have expressive language difficulties.

Investigational Therapies

Dr. Darius Ebrahimi-Fakhari of Boston Children’s Hospital is pursuing a drug screening experiment on cells derived from AP-4-associated HSP patients. The process begins with obtaining skin cells from the patient and the same gender parent. IPSC stem cells are developed from these skin cells and then differentiated into neurons, which can be maintained and studied in a lab. The goal of the project is to test whether various compounds which are FDA-approved for other disorders might offer some benefit to the cells affected by AP-4-associated HSPs. Potentially, the drug screening research may help identify a treatment that benefits all four of these diseases.

Molecular Pathogenesis

AP-4-associated hereditary spastic paraplegia (HSP) is caused by biallelic pathogenic variants in one of four genes (AP4B1, AP4E1, AP4M1, AP4S1) that encode subunits of the AP4 complex (β4, ε, μ4, σ4, respectively). Loss of any one subunit renders the entire heterotetrameric complex nonfunctional; hence, loss-of-function variants in any one of the four genes cause the same cellular outcome – loss of AP-4 complex function [, ]. Reduction or loss of the mutated subunit causes a reduction in the whole-cell level of the other subunits as they are no longer able to be incorporated into a stable complex, and so are degraded by the cell. Evolutionary studies also support the obligate nature of the AP-4 complex because organisms either have all four AP-4 HSP-related genes or none at all [].

The AP-4 complex is ubiquitously expressed in human tissues, including in the central nervous system []. At a steady-state, AP-4 localizes at the subcellular level to the trans-Golgi network (TGN), where it functions in the sorting of transmembrane cargo proteins into transport vesicles for TGN export. In AP-4-deficient cells these cargo proteins will be missorted and so will become mislocalized in the cell, likely affecting their function. A number of proteins have been suggested to be AP-4 cargo proteins. Evidence has emerged supporting a role for AP-4 in the post-Golgi trafficking of the autophagy protein ATG9A (see BioRxiv) [, , ].

AP4B1

Gene structure. The predominant AP4B1 transcript NM_006594.4 consists of 11 exons. Alternatively, spliced transcript variants that encode different isoforms are known.

Normal gene product. The NM_006594.4 transcript encodes the AP-4 complex subunit beta-1 (also known as β4) predicted to be 739 amino acids in length (NP_006585.2) [, ]. The sequence of β4 is strongly conserved through evolution with orthologs in mammals and other vertebrates. β4 assembles into protein complex AP-4 (see Molecular Pathogenesis). β4 domains include one involved in the assembly of the AP-4 complex and a second that binds an accessory protein for AP-4 known as trypsin [].

Abnormal . Most AP4B1 pathogenic variants identified to date predict truncation and/or destabilization of the protein, suggesting that pathogenicity results from the loss of function of the β4 protein [].

AP4E1

Gene structure. The AP4E1 transcript NM_007347.4 consists of 21 exons. Alternatively spliced transcript variants that encode different  are known.

Normal . The NM_007347.4 transcript encodes the AP-4 complex subunit epsilon-1 (also known as ε) predicted to be 1,137-amino acids in length (NP_031373.2) [, ]. The sequence of ε is strongly conserved through evolution with orthologs in mammals and other vertebrates. ε assembles into protein complex AP-4 (see Molecular Pathogenesis). ε domains include one involved in the assembly of the AP-4 complex, and a second shown to bind an AP-4 accessory protein known as tepsin [].

Abnormal . Most AP4E1 pathogenic variants identified to date predict truncation and/or destabilization of the protein, suggesting that pathogenicity results from loss of function of the ε protein [].

AP4M1

Gene structure. The AP4M1 transcript NM_004722.3 has 15 exons. There are multiple splice variants.

Normal . The transcript NM_004722.3 encodes AP-4 complex subunit mu-1 (also known as µ4) predicted to be 453 amino acids in length (NP_004713.2) [, ]. The sequence of µ4 is strongly conserved through evolution with orthologs in mammals and other vertebrates. µ4 assembles into protein complex AP-4 (see Molecular Pathogenesis). The µ4 domains include one that is involved in the assembly of the AP-4 complex, and a protein-protein interaction module known as a Mu homology  that in adaptor protein complexes binds to linear sorting motifs in transmembrane cargo proteins.

Abnormal . Most AP4M1 pathogenic variants identified to date predict truncation and/or destabilization of the protein, suggesting that pathogenicity results from loss of function of the µ4 protein [].

AP4S1

Gene structure. AP4S1 consists of six exons. There are multiple alternative splice variants encoding different protein .

Normal gene product. The NM_007077.4 transcript encodes AP-4 complex subunit sigma-1 (also known as σ4) predicted to be 159 amino acids in length (NP_009008.2) [, ]. The sequence of σ4 is strongly conserved through evolution with orthologs in mammalians and other vertebrates. σ4 assembles into a protein complex, named AP-4 (see Molecular Pathogenesis). σ4 has a 1-142 amino acid region that is involved in the assembly of the AP-4 complex.

Abnormal gene product. Most AP4S1 pathogenic variants identified to date predict truncation and/or destabilization of the protein, suggesting that pathogenicity results from loss of function of the σ4 protein [, ].

The diagnosis: Differential diagnosis is a list of possible conditions that may explain symptoms. সহজ বাংলা: একই লক্ষণের সম্ভাব্য রোগের তালিকা।" data-rx-term="differential diagnosis" data-rx-definition="Differential diagnosis is a list of possible conditions that may explain symptoms. সহজ বাংলা: একই লক্ষণের সম্ভাব্য রোগের তালিকা।">differential diagnosis includes the following:

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: AP-4-Associated Hereditary Spastic Paraplegia

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Is this article a replacement for a doctor?

No. It is educational content only. Patients should consult a qualified clinician for diagnosis and treatment.

When should I seek urgent care?

Seek urgent care for severe symptoms, rapidly worsening condition, breathing difficulty, severe pain, neurological changes, or any emergency warning sign.

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Congenital Enterocyte Heparan Sulfate Deficiency

    DefinitionCongenital? enterocyte heparan sulfate deficiency is a very rare, severe, genetic intestinal disease. In this condition, the small bowel lining cells, called enterocytes, do not show...

    April 3, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  2. Congenital ectropion uveae

    DefinitionCongenital? ectropion uveae, often shortened to CEU, is a very rare eye condition present from birth. In this condition, the dark pigment layer that normally stays...

    April 2, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  3. Congenital Dyserythropoietic Anemia, Type III

    DefinitionCongenital? dyserythropoietic anemia?, type III, also called CDA type III, is a very rare inherited blood disease. In this disease, the bone marrow tries to make...

    April 2, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  4. Congenital Dyserythropoietic Anemia Type I

    DefinitionCongenital? dyserythropoietic anemia?, type I, usually called CDA type I, is a rare inherited blood disease. In this disease, the bone marrow tries to make red...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  5. Congenital Dyserythropoietic Anemia Due to KLF1 Mutation

    DefinitionCongenital? dyserythropoietic anemia? due to KLF1 mutation is a very rare inherited red blood cell disease. In most reported cases, doctors describe it as congenital? dyserythropoietic...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  6. Congenital Dyserythropoietic Anemia Due to KLF1 Mutation

    DefinitionCongenital? dyserythropoietic anemia? due to KLF1 mutation is a very rare inherited red blood cell disease. In most reported cases, doctors describe it as congenital? dyserythropoietic...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  7. HEMPAS – Hereditary Erythroblast Multinuclearity with Positive Acid Serum Test

    DefinitionHEMPAS – Hereditary Erythroblast Multinuclearity with Positive Acid Serum Test is a rare inherited blood disease. Its full old name is hereditary erythroblastic multinuclearity with positive...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  8. Congenital Dyserythropoietic Anemia Type 2

    DefinitionCongenital? dyserythropoietic anemia? type 2, also called CDA type II, is a rare inherited blood disease. In this disease, the body makes red blood cells in...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  9. Component of Oligomeric Golgi Complex 2–Congenital Disorder of Glycosylation

    DefinitionComponent of oligomeric Golgi complex 2–congenital? disorder of glycosylation is usually called COG2-CDG. It is a very rare inherited metabolic disease. In this disease, both copies...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  10. Congenital Disorder of Glycosylation, Type IIq

    DefinitionCongenital? disorder of glycosylation, type IIq, is a very rare inherited metabolic disease. It is now also commonly called COG2-CDG because it is caused by harmful...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)